People In Brief: Bayer’s Mann heads WSMI, infirst has regulatory chief, Zucker leaves Vitacost, OmniActive adds VP

Bayer consumer head chairs global self-care group; Infirst Healthcare names regulatory head; Zucker out as Vitacost chief marketing officer; OmniActive hires marketing VP, relocates HQ; Berholtz moves up at Innovus; MHRA names homeopathic, herbal advisers; more People In Brief.

The World Self-Medication Industry board appoints Bayer Consumer Care President Erica Mann as chair of the global trade association for nonprescription drugs and dietary supplements beginning in June 2014. Mann, who will succeed Chair Zhenyu Guo, CEO of Dihon Pharmaceutical Co. Ltd., has been a member of the Bayer HealthCare LLC Executive Committee and responsible for the Consumer Care division since March 2011 after moving there from Pfizer Inc., where she was president and general manager for the Nutrition Division and a member of the firm’s senior management team. Ferney-Voltaire, France-based WSMI said Sept. 30 that Mann currently is a board member and has held executive posts in organizations including the South African Pharmaceutical Manufacturers' Association, Medicines Australia and the International Association of Infant Food Manufacturers.

Viv Edwards is infirst Healthcare Ltd.’s first director of regulatory and medical affairs, and will help the OTC developer on the road to product commercialization. U.K.-based infirst announced Sept. 16 the appointment of Edwards, who gained more than 15 years of experience in product registration at Procter & Gamble Co., where she most recently was senior regulatory affairs manager for personal health care

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography

US FDA COVID-19 Booster Strategy May Not Be As Controversial As It Seems

 

US FDA Commissioner Martin Makary’s call for placebo-controlled trials to confirm the efficacy of COVID-19 boosters is drawing a lot of criticism, but former Commissioner Robert Califf also supported the idea.

EU Moment Of Truth For Obe-Cel And 10 Other New Medicines

 

Autolus’s CAR T therapy obe-cel is among the medicines that are this week due for an opinion by the European Medicines Agency on whether they should be marketed in the EU.

Blenrep’s Revival Gains Steam: EMA Decision Imminent As Japan Approves New Regimen

 

The European Medicines Agency is due to decide whether GSK’s previously approved multiple myeloma drug that was withdrawn from the market in 2022 should be approved again for use in combination with BorDex or PomDex. Meanwhile, Japan today became the second major regulator to approve the Blenrep combinations.